Humoral response to two doses of BNT162b2 vaccination in people with HIV
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Humoral response to two doses of BNT162b2 vaccination in people with HIV. / Heftdal, Line Dam; Knudsen, Andreas Dehlbæk; Hamm, Sebastian Rask; Hansen, Cecilie Bo; Møller, Dina Leth; Pries-Heje, Mia; Fogh, Kamille; Hasselbalch, Rasmus Bo; Jarlhelt, Ida; Pérez-Alós, Laura; Hilsted, Linda Maria; Ostrowski, Sisse Rye; Gerstoft, Jan; Grønbæk, Kirsten; Bundgaard, Henning; Iversen, Kasper; Garred, Peter; Nielsen, Susanne Dam.
In: Journal of Internal Medicine, Vol. 291, No. 4, 2022, p. 513-518.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Humoral response to two doses of BNT162b2 vaccination in people with HIV
AU - Heftdal, Line Dam
AU - Knudsen, Andreas Dehlbæk
AU - Hamm, Sebastian Rask
AU - Hansen, Cecilie Bo
AU - Møller, Dina Leth
AU - Pries-Heje, Mia
AU - Fogh, Kamille
AU - Hasselbalch, Rasmus Bo
AU - Jarlhelt, Ida
AU - Pérez-Alós, Laura
AU - Hilsted, Linda Maria
AU - Ostrowski, Sisse Rye
AU - Gerstoft, Jan
AU - Grønbæk, Kirsten
AU - Bundgaard, Henning
AU - Iversen, Kasper
AU - Garred, Peter
AU - Nielsen, Susanne Dam
N1 - Publisher Copyright: © 2021 The Association for the Publication of the Journal of Internal Medicine
PY - 2022
Y1 - 2022
N2 - Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.
AB - Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.
KW - antibody response
KW - BNT162b2
KW - HIV
KW - SARS-CoV-2
KW - vaccine
U2 - 10.1111/joim.13419
DO - 10.1111/joim.13419
M3 - Journal article
C2 - 34841629
AN - SCOPUS:85121385903
VL - 291
SP - 513
EP - 518
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
SN - 0955-7873
IS - 4
ER -
ID: 288196331